Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company decreased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 10.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 42,890 shares of the company’s stock after selling 4,814 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.05% of Syndax Pharmaceuticals worth $567,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of SNDX. Assenagon Asset Management S.A. grew its stake in shares of Syndax Pharmaceuticals by 343.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock valued at $27,292,000 after buying an additional 1,598,428 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Syndax Pharmaceuticals in the 4th quarter valued at approximately $9,002,000. Trexquant Investment LP grew its stake in shares of Syndax Pharmaceuticals by 1,309.7% in the 4th quarter. Trexquant Investment LP now owns 471,292 shares of the company’s stock valued at $6,230,000 after buying an additional 437,859 shares during the period. Altium Capital Management LLC purchased a new stake in shares of Syndax Pharmaceuticals in the 4th quarter valued at approximately $4,891,000. Finally, Walleye Capital LLC grew its stake in shares of Syndax Pharmaceuticals by 831.3% in the 4th quarter. Walleye Capital LLC now owns 364,750 shares of the company’s stock valued at $4,822,000 after buying an additional 325,585 shares during the period.

Syndax Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ:SNDX opened at $9.05 on Friday. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $25.07. The firm has a 50-day simple moving average of $12.10 and a 200 day simple moving average of $14.10. The company has a market cap of $778.73 million, a PE ratio of -2.49 and a beta of 0.82.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.06. The business had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. During the same period in the prior year, the company earned ($0.85) EPS. Syndax Pharmaceuticals’s quarterly revenue was up 1900.0% on a year-over-year basis. As a group, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Citigroup dropped their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. StockNews.com raised shares of Syndax Pharmaceuticals to a “sell” rating in a research note on Tuesday, May 6th. Guggenheim reissued a “buy” rating and issued a $32.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 6th. HC Wainwright reissued a “buy” rating and issued a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $35.91.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).